Gilead's Dan O'Day on 1Q23 Earnings

BiotechTV's exclusive interview with Gilead Sciences' Chairman & CEO Dan O'Day on the company's Q1 2023 earnings day.

Brad Loncar visited Gilead Science's headquarters in Foster City, California and had the opportunity to interview Chairman and CEO Dan O'Day about Gilead’s business.

Discussed:

- Gilead’s transformation into oncology and other areas.

- The business model of cell therapy.

- The competitive landscape for the ADC medicine Trodelvy.

- Other oncology targets like CD47 and TIGIT.

- Long-acting medicines for HIV.

- What it was like to develop remdesivir during the pandemic.

Recent Posts

See All

From Seoul: AIGEN Sciences is using generative AI for drug discovery and development - in addition to already having 16 programs, the company earlier this year struck an ADC deal with Hanmi

Visiting the largest cell therapy company in Korea, GC Cell, and learning about its approved immunotherapy for hepatocellular carcinoma, its CAR-NK programs in development, and more

London Healthcare Week: After announcing FIH data from its oral GLP in obesity in September, Terns is also getting ready to release initial data in December for its allosteric BCR ABL cancer program

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.

Visit Klein Hersh